Terbinafine (Lamisilr') in the treatment of onychomycosis

Autor:	Dt Roberts
Rok vydání:	1998
Předmět:	medicine.medical_specialty integumentary system Itraconazole business.industry Fingernail infection Dermatology medicine.disease_cause Griseofulvin chemistry.chemical_compound chemistry medicine Dermatophyte Terbinafine Ketoconazole Toenail infection business Fluconazole medicine.drug
Zdroj:	Journal of Dermatological Treatment. 9:S3-S8
ISSN:	1471-1753 0954-6634
DOI:	10.3109/09546639809160715
Popis:	Terbinafine is a broad-spectrum antifungal agent effective in many different fungal diseases. Its fungicidal effect in vitro is confirmed by several in vivo studies, including a multicentre study of 80 patients with toenail onychomycosis in which terbinafine achieved 82% mycological cure. Twelve weeks has been established as the optimal treatment duration for toenail infection and 6 weeks for fingernail infection. The recommended dose worldwide is 250 mg daily, except in Japan, where 125 mg daily is used for twice the treatment time. Several double-blind, parallel-group studies comparing terbinafine with griseofulvin, itraconazole and fluconazole in the treatment of onychomycosis in both toenail and fingernail disease have shown that terbinafine is significantly more efficacious, as well as cost-effective. A pharmacoeconomic study found terbinafine to be more cost-effective in the management of dermatophyte onychomycosis than griseofulvin, itraconazole or ketoconazole. Minor gastrointestinal effects occur...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::62a33072ec9ae5f6b14c5dbdbd05e13e https://doi.org/10.3109/09546639809160715 Zobrazit plný text záznamu